

1 **Title:** SARS-CoV-2 lethality decreased over time in two Italian Provinces.

2

3 **Authors:** Maria Elena Flacco<sup>1¶\*</sup>, Cecilia Acuti Martellucci<sup>2¶</sup>, Francesca Bravi<sup>3</sup>, Giustino Parruti<sup>4</sup>, Alfonso  
4 Mascitelli<sup>5</sup>, Lorenzo Mantovani<sup>6</sup>, Lamberto Manzoli<sup>1\*</sup>.

5 **Affiliations:**

6 <sup>1</sup> Department of Medical Sciences, University of Ferrara, Italy;

7 <sup>2</sup> Department of Biomedical Sciences and Public Health, University of the Marche Region, Ancona, Italy;

8 <sup>3</sup> "Sant'Anna" University Hospital of Ferrara, Italy;

9 <sup>4</sup> Local Health Authority of Pescara, Italy;

10 <sup>5</sup> Regional Healthcare Agency of Abruzzo, Pescara, Italy.

11 <sup>6</sup> School of Medicine and Surgery, University Bicocca, Milan, Italy.

12

13 **Short title:** SARS-CoV-2 lethality decrease over time.

14 **Key words:** SARS-CoV-2; COVID-19; Case-fatality rate; Mortality.

15 \* [lmanzoli@post.harvard.edu](mailto:lmanzoli@post.harvard.edu) (LM)

16 **Word count:** 1440.

17 **Number of Tables/Figures:** 3.

18

19 ¶ These authors equally contributed to this manuscript.

20

21 **Abbreviations:** COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; CVD,  
22 cardiovascular disease; HR, hazard ratio; RT-PCR, reverse transcription polymerase chain reaction; SARS-  
23 CoV-2, severe acute respiratory syndrome coronavirus 2; SDO, hospital discharge abstract (scheda di  
24 dimissione ospedaliera).

25

26

## 27 **Abstract**

28

### 29 **Background**

30 Some experts recently reported that SARS-CoV-2 lethality decreased considerably, but no evidence is yet  
31 available. This retrospective cohort study aimed to evaluate whether SARS-CoV-2 case-fatality rate  
32 decreased with time, adjusting for main potential confounders.

### 33 **Methods and findings**

34 We included all SARS-CoV-2 infected subjects diagnosed in Ferrara and Pescara provinces, Italy.  
35 Information were collected from local registries, clinical charts, and electronic health records. We compared  
36 the case-fatality rate of the subjects diagnosed during April and March, 2020. We used Cox proportional  
37 hazards analysis and random-effect logistic regression, adjusting for age, gender, hypertension, type II  
38 diabetes, major cardiovascular diseases (CVD), chronic obstructive pulmonary diseases (COPD), cancer and  
39 renal disease. The sample included 1946 subjects (mean age 58.8y; 45.7% males). 177 persons deceased,  
40 after a mean of 11.7 days of follow-up. From March to April, the case-fatality rate significantly decreased in  
41 the total sample (10.8% versus 6.0%;  $p < 0.001$ ), and in any subgroup of patients. Large reductions of the  
42 lethality were observed among the elderly (from 30.0% to 13.4%), and subjects with hypertension (23.0% to  
43 12.1%), diabetes (30.3% to 8.4%), CVD (31.5% to 12.1%), COPD (29.7% to 11.4%), and renal disease  
44 (32.3% to 11.5%). In April, the adjusted hazard ratio of death was 0.42 (95% Confidence Interval: 0.29-  
45 0.60). The mean age of those who died substantially increased from March ( $77.9 \pm 10.8y$ ) to April  
46 ( $86.9 \pm 7.7y$ ).

### 47 **Conclusions**

48 In this sample, SARS-CoV-2 case-fatality rate decreased considerably over time, supporting recent claims of  
49 a substantial improvement of SARS-CoV-2 clinical management. The findings are inevitably preliminary  
50 and require confirmation.

51

52

53 **Author summary**

54

55 **Why was this study done?**

- 56 • Some experts recently reported that SARS-CoV-2 lethality decreased considerably, but no evidence  
57 is yet available.

58

59 **What did the researchers do and find?**

- 60 • We carried out a retrospective cohort study on 1946 SARS-CoV-2 infected subjects from two Italian  
61 provinces, evaluating the potential variation of the case-fatality rate over time.
- 62 • From March to April, in both univariate and multivariable analyses, SARS-CoV-2 case-fatality rate  
63 significantly and substantially decreased, overall and in any subgroup of subjects.

64

65 **What do these findings mean?**

- 66 • The therapies and clinical management of SARS-CoV-2 infected subjects might have substantially  
67 improved over time.

68

69

70

## 71 **Introduction**

72 As of May 18, 2020, SARS-CoV-2 pandemic has caused 320,000 deaths worldwide [1], with largely  
73 discrepant case-fatality rates across countries (from <1% to 16%) [2], likely due to differences in population  
74 age structure [3, 4], variations in testing policies and case recording [5], and/or preparedness of the  
75 healthcare system, which in turn is affected by the intensity of the spread [4, 5].

76 Since the start of the pandemic, Italy has been among the countries with the highest death toll, with more  
77 than 32,000 recorded deaths [1], and an estimated case-fatality rate of 14% [2], which peaked at 20% among  
78 the citizens aged  $\geq 80$  years [6].

79 In the last few weeks, some clinicians suggested that SARS-CoV-2 lethality decreased considerably, mostly  
80 as a consequence of more tailored therapeutic approaches [7-11]. Although the claims were made by expert  
81 physicians, actively engaged in the care of infected patients, the available evidence is anecdotal or based  
82 upon case-studies.

83 We analysed the data of all infected cases in two Italian Provinces to evaluate whether SARS-CoV-2 case-  
84 fatality rate decreased with time, adjusting for main potential confounders.

85

## 86 **Methods**

87 This retrospective cohort study included all subjects infected with SARS-CoV-2, diagnosed in the Provinces  
88 of Ferrara and Pescara, between March 3 (the onset date of the first cases), and April 25, 2020. All  
89 participants were followed up to May 5, 2020. All infections were diagnosed by the central laboratories of  
90 Ferrara University Hospital or Pescara Hospital through RT-PCR (Reverse transcription polymerase chain  
91 reaction) test on nasopharyngeal swabs, and were confirmed by the Italian National Institute of Health.  
92 Information on age, gender, and pre-existing conditions of all participants were collected from local  
93 registries, clinical charts (for hospitalized patients), and through data-linkage with hospital discharge  
94 abstracts (Italian SDO) and the National database of drug prescription. Electronic databases were queried  
95 from the day of the diagnosis until January 1st, 2015. All data have been revised manually by two physicians  
96 (LM and MEF), and the following conditions have been included in the analyses: hypertension, type II

97 diabetes, major cardiovascular diseases (heart failure, myocardial infarction and stroke - CVD), chronic  
98 obstructive pulmonary diseases (COPD, bronchitis, pneumonia, asthma, and emphysema), malignant tumors  
99 and renal disease.

100 The study complies with the Declaration of Helsinki, the research protocol was approved by the Ethics  
101 Committee of the Emilia-Romagna Region (code 287, approved on March 24, 2020), and the requirement for  
102 informed consent was waived because of the retrospective and pseudo-anonymized nature of the data.

103

## 104 **Data Analysis**

105 We compared the case-fatality rate (fatal / confirmed cases) during the first 29 days after the index day (from  
106 March 3 to March 31) with that of the second half of the period (days 30-53; from April 1 to April 25). The  
107 differences between the two periods were initially evaluated using t-test for continuous variables, and chi-  
108 squared test for categorical ones. The potential independent predictors of death were then evaluated using  
109 Cox proportional hazards analysis (using the data censored at May 5, to include  $\geq 10$  days of follow-up). All  
110 covariates were included a priori in the model in their original form, with the exception of age, which was  
111 treated as either continuous or ordinal, to explore the association between the outcome and several age  
112 classes. Schoenfeld's test was used to assess the validity of proportional hazards assumption, and Nelson-  
113 Aalen cumulative hazard estimates to check the validity of constant incidence ratios during the follow-up  
114 [12]. Using the data censored at 20 days of follow-up, a random-effect logistic regression was also fit, with  
115 province as the cluster unit. The same above criteria were used to build the final model. Missing data were  
116  $< 5\%$  in all primary analyses; therefore, no missing imputation technique was adopted. Statistical significance  
117 was defined as a two-sided  $p$ -value  $< 0.05$ , and all analyses were carried out using Stata, version 13.1 (Stata  
118 Corp., College Station, TX, 2014).

119

## 120 **Results**

121 The sample consisted of 1946 subjects (mean age 58.8y; 45.7% males); of them, 31.2% were hypertensive,  
122 12.3% diabetics, and 16.6% with CVD. Some of the characteristics of the sample significantly varied from  
123 March to April. Infected subjects were older by 5.6 years, and the proportion of females, diabetics, subjects  
124 with CVD and renal diseases significantly increased (Table 1).

125 **Table 1. Characteristics of the sample, overall and by time of SARS-CoV-2 infection**  
 126 **diagnosis after the first case (March 3, 2020).**

	Total sample (n=1946)	March 2020 <sup>a</sup> (n=1244)	April 2020 <sup>b</sup> (n=702)	p*
Mean age (SD), years	58.8 (21.3)	56.8 (20.0)	62.4 (23.0)	<0.001
Age-class in years, %				
- <18	3.5	3.9	2.8	0.2
- 18-39.9	14.8	14.7	15.0	0.9
- 40-49.9	15.0	16.6	12.1	0.008
- 50-59.9	19.0	20.1	17.0	0.09
- 60-69.9	13.8	16.1	9.7	<0.001
- 70-79.9	13.2	14.1	11.7	0.13
- ≥80	20.8	14.6	31.8	<0.001
Male gender, %	45.7	50.2	37.9	<0.001
Hypertension, %	31.2	32.9	28.4	0.038
Diabetes, %	12.3	10.6	15.2	0.003
Major cardiovascular diseases, %	16.6	14.6	20.1	0.002
COPD, %	5.6	6.0	5.0	0.4
Cancer, %	7.7	8.3	6.6	0.2
Renal diseases, %	5.9	5.0	7.4	0.029

127  
 128  
 129  
 130  
 131

<sup>a</sup> From March 3 to March 31.

<sup>b</sup> From April 1 to April 25.

\* Chi-squared test for categorical variables, t-test for continuous ones.

132 Overall, 177 persons deceased (after a mean of 11.7 days of follow-up): 135 of the 1244 subjects diagnosed  
 133 in March, 42 of the 702 subjects diagnosed in April. The mean age of those who died substantially increased:  
 134 it was 77.9±10.8 for those diagnosed in March, 86.9±7.7 for those detected in April (p<0.001). In March, 28  
 135 of those deceased were younger than 70 years, and 8 were younger than 60 years. In April, a single death  
 136 occurred in subjects younger than 70 years.

137 From March to April, the overall case-fatality rate significantly decreased (10.8% versus 6.0%, respectively;  
 138 p<0.001 - Fig 1).

139 **Figure 1. SARS-CoV-2 case-fatality rate in the first two months of the pandemic (March and April,**  
 140 **2020), overall and stratified for the most frequent risk classes (all p<0.05). Vertical bars are referred**  
 141 **to 95% confidence intervals.**

142 As shown in Table 2, a reduction of SARS-CoV-2 lethality was observed in any age-class and any category  
 143 of risk. The decrease was however larger among the subjects at higher risk of death: with the lethality  
 144 dropping from 23.4% to 6.1% in the age-class 70-79y, and from 36.3% to 16.1% among the elderly (80+  
 145 years); both  $p < 0.05$ . Similar reductions of the case-fatality rate were observed among the subjects with  
 146 hypertension (from 23.0% to 12.1%), diabetes (from 30.3% to 8.4%), CVD (from 31.5% to 12.1%), COPD  
 147 (from 29.7% to 11.4%), and renal disease (from 32.3% to 11.5%; all univariate  $p$ -values  $< 0.05$ ).

148 **Table 2. Proportion of deaths, overall and by time of SARS-CoV-2 infection diagnosis after**  
 149 **the first case (March 3, 2020), and hazard ratios (HRs) predicting the time to death of patients**  
 150 **diagnosed in April vs March 2020.**

	Total sample	March 2020 <sup>a</sup>	April 2020 <sup>b</sup>	$P^c$	April vs March HR (95% CI)	$P^d$
Overall	9.1	10.8	6.0	$< 0.001$	0.42 (0.29-0.60)	$< 0.001$
Age-class in years, %						
- <18	0.0	0.0	0.0	--	--	--
- 18-39.9	0.0	0.0	0.0	--	--	--
- 40-49.9	0.7	1.0	0.0	0.4	--	--
- 50-59.9	1.9	2.4	0.8	0.3	0.37 (0.04-3.32)	0.4
- 60-69.9	7.5	10.0	0.0	0.007	--	--
- 70-79.9	17.9	23.4	6.1	0.001	0.31 (0.12-0.79)	0.014
- $\geq 80$	25.2	36.3	16.1	$< 0.001$	0.51 (0.33-0.77)	0.002
Gender, %						
- Females	8.0	9.0	6.4	0.12	0.43 (0.27-0.69)	$< 0.001$
- Males	10.4	12.7	5.3	0.001	0.35 (0.19-0.62)	$< 0.001$
Hypertension, %						
- No	4.4	4.9	3.6	0.3	0.43 (0.24-0.78)	0.005
- Yes	19.4	23.0	12.1	0.001	0.45 (0.28-0.72)	0.001
Diabetes, %						
- No	7.5	8.5	5.6	0.025	0.44 (0.29-0.68)	$< 0.001$
- Yes	20.5	30.3	8.4	$< 0.001$	0.36 (0.17-0.76)	0.007
Major cardiovascular diseases, %						
- No	6.3	7.3	4.5	0.023	0.49 (0.30-0.79)	0.003
- Yes	23.0	31.5	12.1	$< 0.001$	0.37 (0.21-0.66)	0.001
COPD, %						
- No	8.2	9.7	5.7	0.003	0.49 (0.33-0.72)	$< 0.001$
- Yes	23.9	29.7	11.4	0.036	0.26 (0.08-0.82)	0.022
Cancer, %						
- No	8.2	9.8	5.5	0.001	0.43 (0.29-0.64)	$< 0.001$
- Yes	19.5	22.3	13.0	0.2	0.47 (0.19-1.18)	0.11
Renal diseases, %						
- No	8.2	9.7	5.5	0.002	0.48 (0.32-0.72)	$< 0.001$
- Yes	22.8	32.3	11.5	0.009	0.20 (0.07-0.54)	0.002

151  
 152 <sup>a</sup> From March 3 to March 31.

153 <sup>b</sup> From April 1 to April 25.

154 <sup>c</sup> Chi-squared test for categorical variables, t-test for continuous ones.

155 <sup>d</sup> Cox proportional hazard model, adjusted for age, gender, hypertension, diabetes, major cardiovascular  
156 diseases, COPD, cancer and renal disease. Some models could not be fit due to the scarce number of deaths.

157

158 Cox analysis substantially confirmed univariate results: adjusting for age, gender, hypertension, diabetes,  
159 CVD, COPD, cancer and renal disease, the hazard ratio (HR) of death of those diagnosed in April, as  
160 compared to March, was 0.42 (95% Confidence Interval - CI: 0.29-0.60 - Table 2). With the only exception  
161 of the subjects with history of cancer, a significantly, considerably lower likelihood of death was observed in  
162 any subset of the sample, with HRs ranging from 0.20 among the subjects with renal disease, up to 0.51  
163 among those aged 80 years or more (Table 2). The results of the random-effect logistic regression did not  
164 vary: overall, the adjusted odds ratio of death at 20 days was 0.29 (95% CI: 0.19-0.45;  $p < 0.001$ ) for those  
165 diagnosed in April, as compared to the subjects detected in March.

166

## 167 **Discussion**

168 This study provides the first evidence of a considerable decrease of SARS-CoV-2 case-fatality rate over  
169 time. From March to April 2020, the death rate decreased by more than 50% in all age-classes, being larger  
170 among the subjects with the highest risk of death because of comorbidities [13, 14]. This finding was  
171 confirmed in all multivariable analyses, adjusting for several potential confounders.

172 It is complex to discern which could be the potential reasons for the observed, entirely novel findings. The  
173 first, most obvious explanation, is that the healthcare system might have been overcrowded during the  
174 epidemic peak in March, with a loss of efficacy [15]. This is however very unlikely to apply to the present  
175 sample, because SARS-CoV-2 infection rates were relatively low - and never exceeded the capacity of the  
176 intensive care units - in the two provinces under analysis [16].

177 Other potential, non mutually exclusive explanations include virus mutation and substantial improvements in  
178 the organization (including the expansion of dedicated hospital beds), therapy and management of the  
179 infected subjects. Some scientists suggested that a less virulent viral strain, with consequent reduced  
180 lethality, might emerge during the pandemic [10]. However, the hypothesis has been contested [17] and is  
181 currently unsubstantiated by data. Concerning the therapy, a growing number of clinicians suggest that the  
182 current therapeutic approach, based upon the early administration of more tailored medications, is



183 considerably improving the clinical course of COVID-19 [7-9, 11]. In the two provinces under investigation,  
184 the treatment is currently based upon antiviral agents (Chloroquine / Hydroxychloroquine or Lopinavir /  
185 Ritonavir), intensive respiratory support [18, 19], and, from the latest days of March, low molecular weight  
186 heparin and monoclonal antibodies against inflammatory cytokines (e.g. Tocilizumab), which showed some  
187 preliminary, promising results [18, 20-23]. Given that available data are anecdotal, only the results of the  
188 several randomized trials that are being conducted on the above treatments [18], will permit to discern which  
189 approach, and to what extent, contributed to the improvement of SARS-CoV-2 infection prognosis.

190 The main limitations of the study are the inclusion of only two provinces from a single country, and the lack  
191 of data on body mass index, which is emerging as significant predictor of death from COVID-19 [24, 25].

192 In conclusion, the present study provided evidence of a significant, considerable decrease of SARS-CoV-2  
193 case-fatality rate between March and April, 2020, supporting preliminary claims on a substantial  
194 improvement of the therapeutic approaches. The findings are inevitably preliminary and require confirmation  
195 from further datasets and ongoing randomized trials.

196

197

198 **Acknowledgments**

199 The authors are grateful to Dr. Giorgia Valpiani and Dr. Nicola Napoli for their valuable help in data  
200 collection.

201

202 **Financial disclosure statement:** This work was not funded.

203

204 **Competing interests:** All authors declare that they have no potential conflict of interest.

205

206

207

## 208 **References**

209

- 210 1. COVID-19 Coronavirus Outbreak [Internet]. Dadax. 2020 [cited March 14, 2020]. Available from:  
211 <https://www.worldometers.info/coronavirus/>.
- 212 2. Johns Hopkins University & Medicine. Coronavirus Resource Center - Mortality Analyses 2020  
213 [May 16, 2020]. Available from: <https://coronavirus.jhu.edu/data/mortality>.
- 214 3. Dowd JB, Andriano L, Brazel DM, Rotondi V, Block P, Ding X, et al. Demographic science aids in  
215 understanding the spread and fatality rates of COVID-19. *Proc Natl Acad Sci U S A*. 2020;117(18):9696-8.  
216 Epub 2020/04/18. doi: 10.1073/pnas.2004911117  
217 2004911117 [pii]. PubMed PMID: 32300018.
- 218 4. Boccia S, Ricciardi W, Ioannidis JPA. What Other Countries Can Learn From Italy During the  
219 COVID-19 Pandemic. *JAMA internal medicine*. 2020. Epub 2020/04/08. doi:  
220 10.1001/jamainternmed.2020.1447. PubMed PMID: 32259190.
- 221 5. Iosa M, Paolucci S, Morone G. Covid-19: A Dynamic Analysis of Fatality Risk in Italy. *Front Med*.  
222 2020;7:185. doi: 10.3389/fmed.2020.00185.
- 223 6. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in  
224 Relation to COVID-19 in Italy. *JAMA*. 2020. Epub 2020/03/24. doi: 10.1001/jama.2020.4683  
225 2763667 [pii]. PubMed PMID: 32203977.
- 226 7. Furuya K, Kato K, Nagata I, Makimura N. [Studies on the blood constituents of the neonates  
227 delivered by the induced delivery of the Defense Medical College method]. *Nihon Sanka Fujinka Gakkai*  
228 *Zasshi*. 1986;38(2):215-22. Epub 1986/02/01. PubMed PMID: 3457089.
- 229 8. Sano M, Sakagami M, Harada T, Matsunaga T, Tominaga Y, Nakayama M. Histopathology of the  
230 temporal bones in thanatophoric dysplasia. *Med J Osaka Univ*. 1991;40(1-4):51-7. Epub 1991/03/01.  
231 PubMed PMID: 1369657.
- 232 9. Scientists disagree: the virus is losing its virulence, but it is forbidden to say it [Quella faida tra  
233 scienziati sul virus: è indebolito ma è vietato dirlo]. *Il Giornale*. May 11, 2020.


- 234 10. Tang X, Wu C, Li X, Song Y, Yao X, Wu X, et al. On the Origin and Continuing Evolution of  
235 SARS-CoV-2. *National Science Review*. 2020;nwaa036. doi: <https://doi.org/10.1093/nsr/nwaa036>.
- 236 11. Di Giambenedetto S, Ciccullo A, Borghetti A, Gambassi G, Landi F, Visconti E, et al. Off-label Use  
237 of Tocilizumab in Patients with SARS-CoV-2 Infection. *Journal of medical virology*. 2020. Epub  
238 2020/04/17. doi: 10.1002/jmv.25897. PubMed PMID: 32297987.
- 239 12. Manzoli L, La Vecchia C, Flacco ME, Capasso L, Simonetti V, Boccia S, et al. Multicentric cohort  
240 study on the long-term efficacy and safety of electronic cigarettes: study design and methodology. *BMC*  
241 *Public Health*. 2013;13:883. Epub 2013/09/26. doi: 10.1186/1471-2458-13-883  
242 1471-2458-13-883 [pii]. PubMed PMID: 24063569; PubMed Central PMCID: PMC3853622.
- 243 13. Williamson E, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. OpenSAFELY: factors  
244 associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult  
245 NHS patients [submitted]. *MedRxiv*. 2020. Epub May 7, 2020. doi:  
246 <https://doi.org/10.1101/2020.05.06.20092999>.
- 247 14. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular Disease, Drug Therapy, and  
248 Mortality in Covid-19. *N Engl J Med*. 2020. Epub 2020/05/02. doi: 10.1056/NEJMoa2007621. PubMed  
249 PMID: 32356626.
- 250 15. Phua J, Weng L, Ling L, Egi M, Lim CM, Divatia JV, et al. Intensive care management of  
251 coronavirus disease 2019 (COVID-19): challenges and recommendations. *Lancet Respir Med*.  
252 2020;8(5):506-17. Epub 2020/04/10. doi: S2213-2600(20)30161-2 [pii]  
253 10.1016/S2213-2600(20)30161-2. PubMed PMID: 32272080; PubMed Central PMCID: PMC7198848.
- 254 16. ProtezioneCivile. COVID-19 Italia - Monitoraggio della situazione 2020 [April 6, 2020]. Available  
255 from:  
256 <http://opendatadpc.maps.arcgis.com/apps/opsdashboard/index.html#/b0c68bce2cce478eaac82fe38d4138b1>.
- 257 17. MacLean O, Orton RJ, Singer JB, Robertson D. No evidence for distinct types in the evolution of  
258 SARS-CoV-2. *Virus Evolution*. 2020;6(1):veaa034. doi: 10.1093/ve/veaa034.
- 259 18. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus  
260 Disease 2019 (COVID-19): A Review. *JAMA*. 2020. Epub 2020/04/14. doi: 10.1001/jama.2020.6019  
261 2764727 [pii]. PubMed PMID: 32282022.

- 262 19. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, et al. Infectious Diseases  
263 Society of America Guidelines on the Treatment and Management of Patients with COVID-19. *Clinical*  
264 *infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020. Epub  
265 2020/04/28. doi: 10.1093/cid/ciaa478. PubMed PMID: 32338708; PubMed Central PMCID: PMC7197612.
- 266 20. Capra R, De Rossi N, Mattioli F, Romanelli G, Scarpazza C, Sormani MP, et al. Impact of low dose  
267 tocilizumab on mortality rate in patients with COVID-19 related pneumonia. *Eur J Intern Med*. 2020. Epub  
268 2020/05/15. doi: 10.1016/j.ejim.2020.05.009  
269 S0953-6205(20)30194-1 [pii]. PubMed PMID: 32405160; PubMed Central PMCID: PMC7219361.
- 270 21. Mazzitelli M, Arrighi E, Serapide F, Pelle MC, Tassone B, Lionello R, et al. Use of subcutaneous  
271 tocilizumab in patients with COVID-19 pneumonia. *J Med Virol*. 2020. Epub 2020/05/16. doi:  
272 10.1002/jmv.26016. PubMed PMID: 32410234.
- 273 22. AIFA. LMWH in adult COVID-19 patients [Eparine a basso peso molecolare nei pazienti adulti con  
274 COVID-19]. In: Italian, Medicines, Agency, editors. Rome2020.
- 275 23. American Society of H. COVID-19 and VTE/Anticoagulation. 2020 May 18, 2020. Report No.
- 276 24. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High prevalence of  
277 obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical  
278 ventilation. *Obesity (Silver Spring)*. 2020. Epub 2020/04/10. doi: 10.1002/oby.22831. PubMed PMID:  
279 32271993.
- 280 25. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in patients  
281 younger than 60 years is a risk factor for Covid-19 hospital admission. *Clinical infectious diseases : an*  
282 *official publication of the Infectious Diseases Society of America*. 2020. Epub 2020/04/10. doi:  
283 10.1093/cid/ciaa415. PubMed PMID: 32271368; PubMed Central PMCID: PMC7184372.
- 284
- 285
- 286

287

288 **Figure 1.**

289



290  
291